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The development of donor-specific anti-human leukocyte
antigen antibodies (DSAs) following renal transplantation
significantly reduces long-term renal graft function and
survival. The traditional therapies for antibody-mediated
rejection (AMR) have provided inconsistent results and
transient effects that may be due to a failure to deplete
mature antibody-producing plasma cells. Proteasome
inhibition (PI) is a novel AMR therapy that deletes plasma
cells. Initial reports of PI-based AMR treatment in refractory
rejection demonstrated the ability of bortezomib to deplete
plasma cells producing DSA, reduce DSA levels, provide
histological improvement or resolution, and improve renal
allograft function. These results have subsequently been
confirmed in a multicenter collaborative study. PI has also
been shown to provide effective primary AMR therapy in
case reports. Recent studies have demonstrated that PI
therapy results in differential responses in early and late
post-transplant AMR. Additional randomized studies are
evaluating the role of PI in transplant induction, acute
AMR, and chronic rejection in renal transplantation.
An important theoretical advantage of PI-based regimens
is derived from several potential strategies for achievement
of synergy.
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The development of anti-human leukocyte antigen (HLA)
antibodies (Abs) specific for the renal allograft is associated
with diminished allograft survival, regardless of whether the
donor-specific anti-HLA antibody (DSA) is de novo or
anamnestic in origin.1–3 However, prompt and complete DSA
elimination may improve allograft survival.4,5
There are currently no immunosuppressive agents
approved by the Food and Drug Administration for
antibody-mediated rejection (AMR) treatment. Historically,
AMR has been treated with a variety of approaches, including
intravenous immunoglobulin (IVIg), therapeutic plasma
exchange, rabbit anti-thymocyte globulin, and rituximab.
These approaches, however, do not deplete the source of Ab
production—the mature plasma cell.6 This limitation may
contribute to the suboptimal and unreliable results observed
with non-plasma cell-depleting agents.
Given the need for reliable and durable elimination of
anti-HLA alloantibodies, considerable efforts are being
focused on developing new antihumoral therapies. Recent
reports have described the use of the proteasome inhibitor
bortezomib (Millennium Pharmaceuticals, Cambridge, MA)
in treating AMR. The utility of bortezomib was first
demonstrated in the treatment of refractory AMR,7 and has
subsequently been shown to provide effective primary
therapy for AMR in case reports.5 The purpose of this
review is to discuss the role of proteasome inhibition (PI) in
AMR treatment.
PROTEASOMES AND PI
The 26S proteasome is a large multimeric enzymatic
structure present in the cytosol of all eukaryotic cells. The
proteasome structurally resembles a cylinder and consists of
a 20S core with 19S regulatory subunits capping each end
(Figure 1). The 20S core consists of four stacked heptameric
rings, with two beta rings surrounded by two alpha rings.
Residing inside of the cylinder, the proteolytic activity of the
proteasome is protected from the cytosol. Three distinct
proteolytic activities exist within the beta ring: chymotryptic-
like, tryptic-like, and postglutamyl (that is, caspase-like)
hydrolyzing activity.8,9 Each alpha ring provides a restricted
opening, which limits the entry of proteins destined for
proteolysis.
http://www.kidney-international.org rev iew
& 2012 International Society of Nephrology
Received 4 June 2010; revised 12 November 2011; accepted 22
November 2011; published online 15 February 2012
Correspondence: E. Steve Woodle, Department of Surgery, Division of
Transplantation, University of Cincinnati College of Medicine, 231 Albert
Sabin Way, ML 558, Cincinnati, Ohio 45267-0558, USA.
E-mail: woodlees@ucmail.uc.edu
Kidney International (2012) 81, 1067–1074 1067
Proteasomal function provides cellular homeostasis via
the selective degradation of misfolded proteins, cell-cycle
regulatory proteins, transcription factors, and inhibitory
molecules.8,9 Bortezomib interrupts this homeostasis through
reversible binding of the b5-subunit, the site of chymotryp-
tic-like proteolytic activity, within the 20S core of the 26S
proteasome.9 PI results in dysregulation of numerous cellular
processes, including antigen processing and mitosis regula-
tion (Figure 2).
The ubiquitin–proteasome system is the major intracel-
lular mechanism for production of peptide fragments of
suitable length for presentation on major histocompatibility
complex (MHC) class I molecules.10,11 This process is
facilitated by the 26S proteasome; however, in inflammatory
states, differing b-subunits with differing enzymatic activities
are produced that provide an alternative array of peptides for
antigen presentation. Cytokine stimulation via interferon-g
enhances immunoproteasome activity as well as upregulates
cell surface MHC class I expression. Through PI, the degree
of antigen processing and presentation on MHC class I
molecules can be inhibited.10,11
There are four major physiological effects of proteasome
inhibitor therapy that are thought to be primarily responsible
for its immunomodulatory effects and likely its effectiveness
in AMR. These include: (1) inhibition of nuclear factor-
kappa B (NF-kB) activity, (2) inhibition of proliferation and
induction of apoptosis via cell cycle arrest, (3) induction of
apoptosis via ER stress, and (4) inhibition of Class I MHC
expression via reduction in endogenous peptide production.
Cell cycle progression is mediated through a precisely
choreographed series of enzymatic events via cyclins.
Throughout mitosis, the synthesis and subsequent degrada-
tion of cyclins is required for cell cycle progression at
multiple checkpoints. The ubiquitin–proteasome system
maintains appropriate levels of these key cyclins.12–14
Interruption of this precise series of events (for example,
viaPI) results in cell cycle arrest and apoptosis.
Protein synthesis and folding are managed within the
endoplasmic reticulum (ER) and are vital for the main-
tenance of normal cellular homeostasis. When a critical
threshold of unfolded or misfolded proteins accumulates
within the ER, a number of protective responses are
generated that comprise the unfolded protein response
(UPR). The UPR is characterized by three major processes:
(1) reduction in synthesis of nascent proteins, (2) upregula-
tion of ER chaperones and foldases, and (3) expression of
proteins that constitute the ER-associated degradation path-
way and facilitate protein trafficking from the ER to the
proteasome.15,16 PI potently induces an UPR due to the
accumulation of high levels of misfolded proteins that have
been targeted for proteasomal digestion. If the accumulation
of misfolded proteins is not controlled, a terminal UPR
results, which consists of mitochondrially and caspase-
mediated cellular apoptosis.15
PI also effectively inhibits production of pro-inflamma-
tory cytokines. NF-kB-mediated transcription of pro-inflam-
matory cytokines is regulated through the binding of
inhibitor nuclear factor-kappa B (IkB) to NF-kB. IkB is
downregulated by ubiquitination and subsequent proteaso-
mal degradation. Therefore, PI results in IkB stability and a
resulting diminishment in production of pro-inflammatory
cytokines such as interleukin (IL)-2, IL-6, IL-10, IL-13,
interferon-g, and tumor necrosis factor-a.13,17 Reduction in
the pro-inflammatory cytokines by PI has also been
demonstrated in anti-CD3-stimulated T cells.18 Reduction
in the inflammatory cytokine milieu improves overall
inflammation and allograft damage, ultimately strengthening
the role of PI in immunologically mediated damage post
transplantation.
PI IN ANIMAL MODELS OF HUMORALLY MEDIATED
AUTOIMMUNE DISEASE
Proteasome inhibitors have been evaluated in animal models
of humorally mediated autoimmune disease. These studies
have provided an enhanced understanding of the effects of
systemic proteasome inhibitor therapy. A disease that closely
mimics systemic lupus erythematosus develops sponta-
neously in NZB/W F1 mice.19 Autoantibodies to double-
stranded DNA mediate glomerulonephritis and play a critical
role in disease progression in this model. Ultimately, these
double-stranded DNA autoantibodies and the associated
glomerulonephritis result in significant mortality in this
model. Neubert and colleagues utilized this animal model to
assess the response to PI with bortezomib and elucidate the
mechanism by which disease amelioration is induced.
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Flow cytometry analysis of CD138þ short- and long-
lived plasma cells from spleen and bone marrow demon-
strated a bortezomib-mediated decrease in both cell populations,
with an overall 95% reduction in the bone marrow
plasma cell population.19 Importantly, when compared to
treatment with dexamethasone or cyclophosphamide, borte-
zomib demonstrated a greater reduction in the total number
of splenic- and bone marrow-derived plasma cells. However,
only bortezomib significantly reduced serum levels of anti-
double-stranded DNA immunoglobulin G levels, which may
have resulted from the induction of a terminal UPR in
plasma cells, as evidenced by the induction of the protein-
folding chaperone BiP. Clinically, reduction in plasma cells
and anti-double-stranded DNA Abs result in amelioration
of glomerulonephritis and prolonged survival. Pathological
examination of bortezomib-treated animals demonstrated
an absence of glomerulitis, vasculitis, and Ab deposition
that was present in control animals. Proteinuria, a marker of
renal dysfunction, also significantly improved with bortezomib
treatment. Notably, infectious complications were not apparent
as mice treated with bortezomib survived for more than
10 months without signs of infection. Given the evidence
presented, bortezomib appears to possess considerable
potential as a plasma cell–depleting agent.
Vanderlugt et al.20 evaluated the effects of PI in a murine
model (SJL/J mouse) of relapsing experimental autoimmune
encephalomyelitis (an experimental model of multiple
sclerosis induced through immunization with myelin protein
eptitopes). Mice treated with the proteasome inhibitor PS-
519 showed improvement in paralysis scores, incidence of
clinical relapse decreased, delay type hypersensitivity reac-
tion, and spinal cord histology.
Palombella et al.21 studied the effects of PI in a Lewis rat
polyarthritis model induced by intraperitoneal injection of
group A Streptococcal cell wall peptidoglycan and poly-
saccharide. This polyarthritis model is characterized by
NF-kB-mediated upregulation of cell adhesion molecules
and proinflammatory cytokines with histology that closely
mimics rheumatoid arthritis. Utilizing several metho-
dologies to assess disease severity, Palombella et al.21
demonstrated improvement in clinical manifestations
of polyarthritis (assessed by the total arthritis index) in
bortezomib-treated animals. Additionally, average hind
paw volume, an objective measure of polyarthritis, was also
markedly reduced in bortezomib-treated animals. Finally,
histology of hind paw joints at necropsy demonstrated
a reduction in cellular infiltrates as well as an attenuation
of the degradation of articular cartilage and erosion of
subchondral bone.
BORTEZOMIB THERAPY IN TRANSPLANTATION
Three studies have examined potential roles for proteasomes
and PIs in transplant rejection models. Luo et al.18 evaluated
the PI dipeptide boronic acid (DPBA) and found it to
suppress T-cell proliferation and IL-2, IL-6, IL-10, IL-13, and
g-interferon production in vitro in response to anti-CD3
monoclonal Ab. Short-term administration of DPBA (16
days) was found to prolong murine heart allograft survival
for up to 35 days compared with 7 days in control mice. This
group of investigators also examined DPBA in a murine
islet allograft model.22 In this experience, the authors first
demonstrated that DPBA suppressed mixed lymphocyte
reactions and cytotoxic T-cell generation in vitro. In murine
islet transplant recipients, a 17-day DPBA course provided
50% islet allograft survival at 60 days, whereas control mice
demonstrated islet allograft rejection at 7 days. No effect
of DPBA was found on islet function following glucose
challenge. In a more recent study, administration of
bortezomib on day 20 following MHC-mismatched heart
transplantation prolonged cardiac allograft survival to 31.7
days compared with 6.3 days in untreated controls.23 The
authors also found lower levels of anti-MHC class I and II
Abs at 7 days following transplantation. In a chronic AMR rat
cardiac transplant model, administration of bortezomib
beginning at 60 or 80 days following transplantation reduced
anti-donor MHC class I and II Abs. Histological improve-
ments were also observed with bortezomib administration,
including reduction in C4d expression, interstitial fibrosis,
and vasculopathy.23
Recent clinical experiences have provided evidence for the
ability of proteasome inhibitor-based regimens to reverse
AMR. In the first report of bortezomib in renal transplanta-
tion, we treated a series of patients with refractory mixed
acute rejection, defined as biopsy-proven rejection meeting
the Banff criteria for both AMR and acute cellular rejection.7
In this report, six patients treated with refractory mixed acute
rejection were treated for eight rejection episodes. Each
rejection episode was treated with one cycle of bortezomib
(4 doses of 1.3mg/m2). Two patients received an additional
bortezomib cycle for recurrent rejection. In all cases, these
mixed acute rejection episodes had previously failed multiple
therapies, including plasmapheresis, rituximab, rabbit anti-
thymocyte globulin, and IVIg.
Immunodominant DSA (iDSA), which is defined as the
highest-level DSA at the time of rejection diagnosis, was used
as the marker of AMR treatment efficacy. Bortezomib therapy
reduced iDSA levels by more than 50% in all cases.7 This
includes one case where bortezomib was administered alone
with plasmapheresis and resulted in 470% reduction in the
iDSA and a 490% reduction in other DSA specificities.
Interestingly, the majority of iDSA specificities were MHC
class II specificities, and half of all the rejection episodes had
an HLA-DQ specificity for the iDSA. Previously, it has been
suggested that MHC class II Abs are generally more
refractory to treatment.24
Renal function improved or remained stable in the
majority of rejection episodes. Also notably, renal allograft
biopsies showed that all patients experience resolution or
improvement in acute cellular rejection, including one
patient with a Banff grade IIA acute cellular rejection, in
which a severe endotheliitis completely resolved with
bortezomib treatment.7
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In this initial experience, the toxicity profile of bortezomib
was reasonable, as only two patients were reported to
experience adverse events.7 One patient experienced transient
thrombocytopenia and diarrhea (which resolved with anti-
diarrheal therapy). Another patient experienced febrile
neutropenia (without infection), which resulted in holding
of the final dose of bortezomib. Neutropenia was attributed
to the additive effects of multiple immunosuppressants
and anti-infective agents in this patient. Opportunistic
infection and malignancy were not reported for any patients.
This case series demonstrates the ability of bortezomib to
provide a marked reduction in DSA levels, resolution of
allograft biopsy histology, and improvement in allograft
function.
A subsequent report described the use of bortezomib in
combination with daily plasmapheresis and IVIg in two
positive cross-match kidney recipients with AMR.25 One
patient was highly sensitized pre-transplant and exhibited a
flow cross-match channel shift4300. This patient received a
perioperative plasmapheresis and IVIg protocol, with AMR
developing during treatment with this protocol. The second
patient was less sensitized initially, and therefore did not
receive the perioperative plasmapheresis and IVIg protocol.
Both patients received bone marrow biopsies at the time of
AMR and 1 week following treatment to assess therapeutic
response to AMR treatment with bortezomib.
Both patients had numerous alloantibody specificities at
the time of AMR, both donor specific and third-party anti-
HLA Abs.25 Ab levels were measured, by single antigen anti-
HLA beads, at the time of rejection and 1 year following
bortezomib treatment. In both patients, the total number of
allospecificities and levels of remaining Abs were reduced in
response to treatment with bortezomib. Bone marrow
aspirates in these two patients showed that the percentage
of plasma cells in bone marrow declined in response to
bortezomib therapy. One year post transplant, both patients
maintain normal renal function and transplant glomerulo-
pathy was absent on protocol biopsies. Notably, total
immunoglobulin levels were normal in both patients despite
the absence of DSA-producing plasma cells.
Bone marrow biopsies done during AMR treatment in
these patients provide a unique perspective on the effects of
bortezomib on bone marrow–resident plasma cells.25 An
ELISpot assay for the detection of antitetanus Ab demon-
strated a greater than 50% reduction in Ab production in
bone marrow–derived plasma cells treated with bortezomib.
More recently, PI with bortezomib has been evaluated as
the primary therapy for AMR in a series of two patients.5
Both patients were treated with the combination therapy,
which consisted of bortezomib, rituximab, and plasmapher-
esis. Bortezomib (1.3mg/m2) was given on treatment days 1,
4, 8, and 11. Patients received plasmapheresis before each
bortezomib dose and every other day for 3 sessions beginning
72 h after the final bortezomib dose. Rituximab (375mg/m2)
was administered on treatment day 1 following bortezomib
and plasmapheresis. A representation of the histological and
immunological improvement seen with bortezomib-based
therapy is depicted in Figure 3.
The first patient developed AMR on post-transplant day
13 following his third kidney transplant.5 Although DSAs
were absent before the transplant, an acute rise in creatinine
level on post-transplant day 13 prompted a renal allograft
biopsy, which demonstrated C4d immunostaining of the
peritubular and glomerular capillaries (Figure 3a and b).
High levels of DSAwere detected on single HLA-antigen bead
testing by Luminex. Bortezomib-based treatment was ini-
tiated on post-transplant day 14. Following treatment, DSA
was undetectable (Figure 3) and repeat renal allograft biopsy
on post-transplant day 28 demonstrated a reduction in
glomerular and peritubular capillary C4d staining (Figure 3c
and d). Serum creatinine levels returned to pre-rejection
baseline and proteinuria was not observed.
The second patient to receive bortezomib-based primary
therapy for AMR was a 41-year-old woman who received a
one-haplotype-matched living donor kidney transplant from
her son.5 DSA was absent before transplant, but a low-level
DSA was detected through surveillance on post-transplant
day 7. DSA continued to rise, and on post-transplant day 13 a
renal allograft biopsy demonstrated faint peritubular capil-
lary and strong glomerular capillary C4d staining. DSA was
also markedly increased, and treatment was initiated on post-
transplant day 15. Plasmapheresis was done before the first
two bortezomib doses, but otherwise held to reduce risk of
bleeding complications from recent surgical procedures.
Treatment response included DSA elimination, return of
serum creatinine levels to baseline, and resolution of
proteinuria. Approximately 2 months following initial
treatment, the patient developed recurrent DSA elevation
without renal dysfunction, which was treated with a second
course of bortezomib-based therapy. Again, DSA was
decreased below level of detection and serum creatinine level
remained stable. Interestingly, the iDSA of the first rejection
episode (anti-HLA B7) was absent during the second
rejection episode. This suggests that plasma cell clones
responsible for producing anti-HLA B7 Abs were durably
depleted by the first bortezomib course.
This first report on bortezomib primary therapy also
demonstrated the relative safety of bortezomib-based AMR
treatment protocols.5 Mild anemia was reported for both
patients, which likely represented an artifact of end-stage
renal disease given the early post-transplant course. Addi-
tionally, the second patient experienced mild nausea,
vomiting, and diarrhea. During the second rejection episode,
the second patient also experienced transient peripheral
neuropathy, which completely resolved within 3 days. In
short, these cases illustrate the ability of bortezomib-based
therapy for early post-transplant AMR to completely
eliminate DSA, improve renal biopsy histology, and return
renal function to baseline, with limited toxicity.
Recently, Legendre and colleagues26 presented clinical data
suggesting that bortezomib alone is not effective in reducing
DSA levels in a case series of four patients. Conclusions from
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this study, however, are significantly compromised by several
considerations. First, patients were treated with bortezomib
for clinically silent AMR (also termed subacute or subclinical
AMR), a lesion that has only recently been described.27–29 As
such, subclinical AMR has not yet been recognized in the
Banff grading system as a distinct entity, and its responsive-
ness to any AMR therapy remains to be defined. More
importantly, no renal allograft biopsy was performed in these
four patients earlier than 1 month prior to bortezomib
therapy (actual times include biopsy at 1, 1, 3, and 5 months
before bortezomib therapy). Therefore, it is impossible to
ascertain what lesion was actually being treated in these
patients. Moreover, no patient received a follow-up biopsy,
thereby precluding assessment of the histological response
to therapy. In addition, since serum creatinine level was not
elevated in any patient, renal function could not be evaluated
as an efficacy criterion. Therefore, the only evaluable criterion
to assess efficacy in this study were DSA levels. We have
previously shown that DSA reductions in response to
any type of therapy for late post-transplant AMR are
diminished.30
The authors assert that there are many possibilities for the
apparent lack of effect on DSA levels. One factor may be that
corticosteroids (which were eliminated by the authors from
the bortezomib regimen) may be synergistic with bortezo-
mib.26 Given that oncologists almost universally use corti-
costeroids in conjunction with bortezomib, it is surprising
that the removal of corticosteroids from this treatment
protocol was attempted. Also, the relatively stable and low
level of DSA indicates a low metabolic state of plasma cells,
which may offer protection from PI-induced UPR. Plasma
cells, which are metabolically active and produce high levels
of immunoglobulin, have been shown to be more susceptible
to UPR induction by PI.31 Additionally, late post-transplant
AMR may represent a more difficult clinicopathological
etiology to treat as it is likely predominated by bone marrow
survival niche–resident plasma cells.5
Of interest, patients treated in this study exhibit a unique
side-effect profile.26 Three out of the four patients treated
experienced bilateral conjunctivitis. Patients also complained
of a generalized weakness that lasted up to a month following
the final dose of bortezomib. More typically, nausea,
vomiting, and diarrhea were each experienced by one patient.
Hematological toxicities and infectious complications were
not noted in these patients.
More recently, large experiences with proteasome inhibi-
tor–based treatment of AMR have been published.30,32 We
compared the results of bortezomib-based therapy by
examining the results in 13 early and 17 late (46 months)
post-transplant AMR episodes. This comparison has illu-
strated the dichotomous nature of AMR responses.30 Patients
with early post-transplant AMR were more likely to have
been sensitized before transplant, and to demonstrate a larger
reduction in DSA levels and greater improvement in renal
allograft biopsy histology with bortezomib treatment. In all
early AMR patients, bortezomib-based therapy resulted in
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significant improvement in renal function. Interestingly, late
AMR was more often associated with a DSA directed against
the HLA-DQ specificity, and pre-treatment DSA levels were
significantly higher than in patients with early AMR.
However, late AMR episodes demonstrated a lesser magni-
tude of improvement in DSA levels and renal function. These
findings indicate that late post-transplant AMR tends to be
less responsive than early acute AMR to treatment.
Flechner et al.32 have reported their experience with
bortezomib-based AMR treatment in kidney transplant
recipients. In this experience, patients with higher serum
creatinine levels at the time of initiation of AMR therapy
demonstrated reduced therapeutic responses, suggesting that
more severe or more established AMR episodes may
demonstrate diminished therapeutic responses.
Initial results from a multicenter collaborative utilizing a
single proteasome inhibitor-based regimen were very similar
to those obtained in our initial report on the effectiveness of
bortezomib in AMR.33 Eighty-one patients treated for 96
AMR episodes with a common bortezomib-based regimen
demonstrated substantial DSA reductions with bortezomib-
based therapy, with more than half of the patients
achieving a 450% reduction in iDSA level. In addition, this
collaborative experience demonstrated that the bortezomib-
based regimen reversed AMR in adult kidney, kidney/
pancreas, and pediatric heart transplant recipients. It is
important to note that in bortezomib-based regimens
plasmapheresis has been performed every third day
immediately before bortezomib therapy. This is in contrast
to IVIg-based regimens where plasmapheresis has tradition-
ally been reported to be performed more frequently—either
daily or on alternate days.
Bortezomib has also been shown to reduce DSA and third
party anti-HLA Ab levels in patients without AMR.34 In this
report, 11 patients transplanted under a clonal stimulation
and deletion protocol were treated for anti-HLA Abs
appearing within the first 100 days post-transplant. Treat-
ment included bortezomib (1.3mg/m2) on days 1, 4, 8, and
11 of treatment. Methylprednisolone 250mg was adminis-
tered concomitantly with each bortezomib dose. In 6 of the
11 cases, rituximab was included as adjuvant therapy. In the
majority of patients treated, anti-HLA Ab levels, including
those directed against the donor, were reduced below 1000
mean fluorescence intensity in a median time of 24 days from
treatment initiation.34 Two patients, both with peak Ab levels
410,000 mean fluorescence intensity, did not reduce Ab
titers to o1000 mean fluorescence intensity. However,
following treatment, both patients exhibited a 450% reduc-
tion in primary Ab. Notably, at the last follow-up, Ab levels in
both refractory cases had rebounded to near peak levels.
However, despite high levels of Ab, serum creatinine level
remains stable throughout in both cases. However, given the
relatively short length of follow-up, it will be prudent to
examine the long-term sequelae of elevated DSA levels in
these patients. Significant data supporting the detrimental
effects of DSA on allograft survival exist.1–3
Bortezomib therapy was tolerated well in this patient
population.34 The most prevalent adverse event was diarrhea;
however, the authors indicate that the etiology of this cannot
be distinguished owing to the endemic nature of diarrhea in
the region. Thrombocytopenia was reported in all patients
treated with bortezomib. Additionally, one patient reported
generalized weakness, which resolved following treatment.
Opportunistic infections were not observed in this patient
population.
PI IN TRANSPLANTATION: CONSIDERATIONS FOR ONGOING
AND FUTURE STUDIES
As with all immunosuppressive agents developed to date, the
efficacy of bortezomib may be enhanced when used within
the context of combination regimens. Rituximab is an agent
that has considerable potential for enhancing the efficacy of
proteasome inhibitor-based regimens. Rituximab alone has
been used previously to treat AMR and offers the ability to
deplete naive and memory B-cell precursors of plasma cells.
However, rituximab-based regimens have not demonstrated
the ability to durably reduce DSA levels,35 possibly because of
its lack of effect on plasma cells.6,25
Therapeutic plasma exchange also has been used in the
treatment of rejection, but acts simply to mechanically
remove preformed Abs in circulation. The combination of all
three aforementioned agents has demonstrated significant
efficacy.5 It is suggested that in this combination therapeutic
plasma exchange serves two roles: (1) reduction in negative
feedback inhibition experienced by alloantibody-producing
plasma cells, thus making them more metabolically active
and susceptible to targeting by PI, and (2) providing a timely
and accurate reflection of the true Ab production capability
by removing existing circulating Abs.5
Our approach toward examining the efficacy of bortezo-
mib for AMR treatment has been conservative and we have
restricted the initial patient population to a maximum of two
cycles of therapy.5,7 However, in the multiple myeloma
population a median of six cycles of bortezomib have been
used with a reasonable adverse event profile, and many
patients are treated for a year or more.36 As greater
experience with bortezomib in the transplant population is
gained, maximization of therapy will be evaluated. Additional
cycles of bortezomib may result in a greater durability in
alloantibody depletion and improved long-term outcomes.
Recent data indicated that up to four cycles are well tolerated
in highly sensitized waitlist patients undergoing bortezomib-
based desensitization.37
Bortezomib is a first-in-class proteasome inhibitor devel-
oped for its anti-neoplastic properties. Currently, there are
several second-generation proteasome inhibitors under
development for use in the oncology population.38 Desired
improvements include a greater activity against the pro-
teasome, as well as an improved safety profile. Ease of
administration is also one improvement being targeted, with
the orally bioavailable proteasome inhibitor PR-047 currently
being investigated.38
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Bortezomib may be combined with other agents to
enhance therapeutic efficacy. As with a number of cancer
agents, drug resistance may be mediated by p-glycoprotein;
therefore p-glycoprotein inhibitors may be useful in enhanc-
ing bortezomib efficacy. Similarly, autophagy inhibitors,
such as histone deacetylase inhibitors, may also be useful in
potentiating bortezomib therapy. Other new agents that
inhibit humoral responses may be reasonable to use in
combination with bortezomib, such as BAFF or April
inhibitors or IL-6 inhibitors.
The role of PI in transplantation will not be limited to
AMR treatment. It will also be important to ensure that the
development of treatment strategies be done under carefully
designed and executed clinical trials. Currently, we are
conducting controlled trials examining the use of bortezomib
in desensitization protocols, induction strategies, and chronic
rejection (http://www.clinicaltrials.gov). Additionally, the use
of bortezomib is being evaluated in patients receiving solid
organ transplants other than kidney.39–41
We recently outlined a number of issues related to clinical
trial design and conduct for antihumoral agents seeking the
FDA approval for acute and chronic AMR therapy,
desensitization, and AMR prevention.42 For AMR in
particular, development of end points will be important. To
date, we have used three criteria for assessing therapeutic
responses when treating AMR: (1) renal function, (2) renal
allograft histology, and (3) DSA levels. Currently, the assay
for assessing DSA levels is being optimized and validated by
several groups. Our preliminary data indicate that serum
creatinine levels and repeat allograft biopsy could likely be
reasonable end points; however, a careful examination of
Banff components will be necessary.
CONCLUSION
The elimination of DSA improves renal allograft outcomes,
but the question of which approach is most suited for the
abrogation of DSA remains to be established. Historical
therapies, such as plasmapheresis, rituximab, rabbit anti-
thymocyte globulin, and plasmapheresis, do not deplete anti-
HLA Ab-secreting plasma cells.6,7 Proteasome inhibitor-based
regimens have provided an alternative strategy for AMR
treatment. An important advantage of proteasome inhibitor-
based strategies for targeting plasma cells is the large number
of potential synergistic strategies that can be employed to
enhance their effects on plasma cells.
The greatest advantage of proteasome inhibitor-based
protocols over IVIg-based regimens is the number of strategic
approaches that exist for achieving synergy with proteasome
inhibitors. A fundamental understanding of the biology of
protein degradation pathways and clinical development of
new agents targeting differing components of these pathways
are requisite steps in developing synergistic plasma cell
depletional combination regimens. Therein lies a very
promising pathway for addressing the previously almost
impenetrable barrier presented by the production of extra-
ordinarily high levels of HLA alloantibodies by bone marrow
niche–resident plasma cell clonal populations. The future of
antihumoral therapies in clinical transplantation has never
been more exciting.
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